Perspective24 May 2024 19:03
I feel Valirx is being judged on past performance by many.
If the company were a new entity there would be a great deal of excitement created from the recent announcement.
In some respects Valirx could be viewed as a new entity, indeed with 3 new additions to the board and recruiting for a new CEO the board structure has been transformed.
Couple that with the progress made recently.
*Ongoing evaluation projects.
*INAPHAEA
Setting up the lab to the make progress of evaluation projects both more cost effective and creating an environment for development.
Being on the verge of commerciality after a period of developing its services.
*Two clinical stage assets.
*CLX001. Showing great promise, recently receiving a grant from the OP with its lead formulation currently going through safety tests.
I am clearly a shareholder and for many reasons want the company to do well.
There will be people with a legitimate opposing view and some with an agenda who will do and say anything to discredit the company but I remain very optimistic for the future of Valirx.